Abstract
Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
| Original language | English |
|---|---|
| Pages (from-to) | 128-135 |
| Number of pages | 8 |
| Journal | IDrugs |
| Volume | 9 |
| Issue number | 2 |
| State | Published - Feb 2006 |